How Long Do Hot Flashes Last? The Surprising Truth
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 15 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
How long do hot flashes last? SWAN data show a median 7.4 years, with 4.5 years after the final period. The surprising truth and what it means for treatment.
It's crazy to me that there's this really absolute cultural silence about menopause. Most people have a general concept of puberty. When a woman doesn't know what to expect when she's no longer expecting a period, she doesn't know what's happening to her body.
If you’re asking how long hot flashes last, you’ve probably been told a confident-sounding number — “two to five years,” “until you stop having periods” — that doesn’t match what you or someone you know is experiencing. The honest answer, drawn from the longest-running longitudinal study of the menopause transition, is substantially longer than the older estimates. For most women, hot flashes last more than seven years. For one in ten, they continue into the 70s.
This guide walks through what the best data show, why women have been routinely under-told the actual duration, what factors predict where you’ll fall in the range, and what the timeline means for whether and how to treat.
Key takeaways
The median duration of hot flashes and night sweats is 7.4 years, according to the SWAN longitudinal cohort — substantially longer than older estimates of two to five years.
About 4.5 of those years typically occur after the final menstrual period, not before it.
Roughly one in ten women continue to experience hot flashes into their 70s.
Duration varies meaningfully by race and ethnicity, age of symptom onset, BMI, smoking status, and the trajectory pattern of your individual symptoms.
Symptom duration is independent of whether you treat — hormone therapy and other treatments manage symptoms for as long as you use them, but don’t change the underlying biological timeline.
The short answer
The largest and most-cited dataset on vasomotor symptom (VMS) duration comes from the Study of Women’s Health Across the Nation (SWAN). Avis and colleagues, publishing in JAMA Internal Medicine in 2015, reported a median total VMS duration of 7.4 years in a multi-ethnic cohort of more than 1,400 women followed across the menopause transition. Of that total, a median of 4.5 years of symptoms occurred after the final menstrual period.
That median hides substantial variation. Some women have hot flashes for one to two years and stop. Others continue for fifteen years or more. The distribution is wide enough that no single duration estimate captures most women’s experience well, but the median number is meaningfully longer than what many women have been told in clinical visits over the last twenty years.
The reason this matters isn’t to brace yourself for a fixed sentence. It’s to make decisions about treatment with a realistic understanding of what you’re managing. If you’re three years into hot flashes and waiting for them to stop, the median woman has another four-plus years to go. That’s not a reason to suffer; it’s a reason to consider whether treatment is worth pursuing rather than waiting it out.
Where the older numbers came from
For decades, the standard clinical answer to “how long will my hot flashes last?” was something like “two to five years” or “until you go through menopause.” That answer wasn’t pulled from nowhere — it came from earlier cross-sectional studies and clinical impressions that systematically underestimated duration. Several reasons:
Cross-sectional studies asked women at one time point about current symptoms, which underestimates the total duration of an episode that spans years.
Recall bias in retrospective studies tends to compress symptom duration in memory; women asked years later about how long their hot flashes lasted often report shorter intervals than longitudinal tracking shows.
Clinical experience in primary care often saw the women whose symptoms had improved, not the ones who continued to suffer; women whose symptoms persisted often stopped seeking care after being told nothing more could be done.
The framing of menopause as a “transition” carried an implicit assumption of finite duration, even though the underlying VMS biology can persist long after the transition is “complete.”
SWAN changed the picture because it was designed to track women prospectively across the transition, in a diverse multi-ethnic sample, with structured symptom assessments at regular intervals. The 7.4-year median emerged from that design, not from new biology — it had been true all along, but no prior dataset was set up to see it cleanly.
The clinical implication: if a clinician tells you to expect “a few years” of hot flashes, that estimate predates the evidence we now have. The realistic median is longer, and the planning horizon should reflect that.
The four trajectory patterns
Further analyses of the SWAN cohort identified roughly four distinct VMS trajectories. Each describes a different pattern of when symptoms start, peak, and resolve.
Early-onset trajectory. Symptoms begin years before the final menstrual period — sometimes in the late reproductive stage or early perimenopause — and persist through the transition. For women in this pattern, total duration is often more than a decade, but symptoms tend to ease in early postmenopause as estrogen stabilizes at a new baseline. This is the longest-symptom group overall.
Late-onset trajectory. Symptoms begin around or after the final period. Total duration is often shorter than the median, and symptoms typically persist for several years into postmenopause before resolving.
Persistently high trajectory. Symptoms are frequent and severe across the entire transition and continue at high frequency well into postmenopause. This is the group most likely to experience VMS into the 70s.
Persistently low or absent trajectory. A smaller group has few or no vasomotor symptoms throughout the transition. About 20-25% of women fit this pattern.
Knowing which trajectory your symptoms appear to fit isn’t a parlor trick. It informs how aggressively to treat early, what to expect over the next several years, and how to think about the duration question. An early-onset pattern with severe symptoms suggests a longer trajectory ahead; a late-onset pattern that started after the final period may resolve within a more typical window.
What predicts where you fall in the range
The brain is exquisitely sensitive to estrogen and progesterone. It's had these hormones in a particular pattern its whole life, and now that pattern is broken. That's not a character flaw. That's physiology.
Several factors are consistently associated with longer or shorter VMS duration in the SWAN data and in subsequent analyses.
Race and ethnicity. The SWAN data on differential VMS duration are robust. Black women experienced the longest median duration at 10.1 years. Hispanic women had a median of 8.9 years. Non-Hispanic white women had a median of 6.5 years. Chinese and Japanese women had the shortest medians, at 5.4 and 4.8 years respectively. The drivers of these differences — genetic, environmental, social, structural — are still being characterized.
Age of symptom onset. Earlier onset predicts longer total duration. Women whose hot flashes begin in the late reproductive or early perimenopausal stage experience symptoms for many more years than women whose flashes appear only after the final period.
Smoking. Current smoking is associated with both earlier menopause (by about one to two years on average) and longer, more intense vasomotor symptoms. Quitting reduces VMS frequency, sometimes within months.
Body mass index. Higher BMI is associated with both more frequent and longer-duration VMS in SWAN. The mechanism is multifactorial and includes thermoregulatory load and possibly inflammatory effects of visceral adipose tissue.
Mood symptoms. Anxiety and depression are both associated with more severe and more persistent VMS, partly because they amplify perceived severity and partly because they reduce the use and adherence of effective treatments.
Surgical or medical induction. Bilateral oophorectomy, chemotherapy, or hormone-blocking treatments produce more abrupt estrogen withdrawal and often more severe VMS than gradual natural decline. Duration patterns can differ. Our guides on surgical menopause and tamoxifen side effects cover these specific clinical contexts.
Genetics. Family history is one of the stronger predictors. If your mother and sisters had long-lasting hot flashes, you’re more likely to. The genetic contribution is being worked out but is not yet clinically actionable at the individual level.
When hot flashes start matters more than when they “should” stop
A practical framing that’s more useful than worrying about the end date is paying attention to when symptoms start. The trajectory data suggest the start point is a reasonable predictor of total duration.
If your first hot flashes appeared in your late 30s or early 40s, well before your periods became irregular, you’re probably in an early-onset pattern. Total duration is often long. Symptom intensity often peaks in late perimenopause and early postmenopause and then attenuates.
If your first hot flashes appeared after cycle irregularity was already established — typical late perimenopause — you’re probably in a more typical trajectory. The median duration estimates apply most directly.
If your first hot flashes appeared after your final period, you’re probably in a late-onset pattern. Total duration may be shorter than the median, though symptoms can still last several years.
If you’re not having hot flashes at all in late perimenopause or early postmenopause, you may be in the persistently low or absent group, which represents about a quarter of women.
None of these patterns are deterministic, and individual courses can diverge from any prediction. But the trajectory framework gives you a more realistic mental model than “they should be over in a couple of years.”
What this means for treatment decisions
A common misconception is that treatment should be reserved until you’ve “tried to ride it out.” The trajectory and duration data don’t support that framing.
If your symptoms are interfering with sleep, work, mood, or daily function, the realistic timeline is years, not months. The cost of waiting it out — months or years of disrupted sleep, increased cardiovascular risk markers, declining quality of life — is substantial when the underlying biology won’t resolve quickly.
The treatment options that work haven’t changed, but the urgency to consider them has. The Menopause Society 2022 Hormone Therapy Position Statement and NICE Guideline NG23 (updated November 2024) endorse hormone therapy as first-line for moderate-to-severe vasomotor symptoms in appropriately selected women under 60 or within 10 years of their final period. For women who can’t or don’t want hormones, fezolinetant (a non-hormonal NK3 receptor antagonist) and several evidence-supported medications including low-dose SSRIs, SNRIs, gabapentin, and oxybutynin offer meaningful options.
Treatment also doesn’t lock you in. Most women can taper or stop hormone therapy after several years and assess what residual symptoms remain. Some have minimal residual symptoms; others find that flashes return at similar intensity and choose to continue therapy. The decision is reversible.
For deeper context on what’s actually happening biologically and why it persists for so long, see our pillar on what causes hot flashes, which covers the KNDy neuron mechanism. For practical management options, see how to stop hot flashes and our overviews of Veozah (fezolinetant) and medication for hot flashes.
When hot flashes do eventually end, what happens?
For most women, hot flashes resolve gradually rather than stopping abruptly. The end of the symptomatic period is often hard to pinpoint precisely. You may notice that the frequency falls off over months, that severity diminishes, that flashes become more situational (triggered by specific events rather than appearing unprompted), and that they eventually disappear from your experience without a clear endpoint.
Some women experience a brief recurrence of symptoms after a period of resolution, often in response to a specific stressor or illness. This is not uncommon and doesn’t generally signal that the symptomatic period is starting over. Genitourinary symptoms (vaginal dryness, urinary urgency, painful intercourse) follow a different pattern and often emerge after vasomotor symptoms have resolved — they typically worsen with sustained estrogen deficiency rather than improving. Our guide on is vaginal estrogen safe covers GSM management.
When to talk to your doctor
I've heard people say, 'perimenopause and menopause are just natural parts of life, like women have dealt with it for all of humankind.' Just because something is natural doesn't mean we have to tolerate it.
Reasonable triggers for a clinical conversation include:
Hot flashes disrupting sleep more than two nights per week
Hot flashes interfering with work, social function, or daily activity
New or worsening anxiety, depression, or cognitive symptoms accompanying VMS
VMS that started before age 45, particularly before age 40
VMS following surgical removal of the ovaries, chemotherapy, or hormone-blocking treatment
VMS persisting beyond the “couple of years” you may have been told to expect, with declining quality of life
Wanting to discuss whether to start, change, or stop treatment
If you’re preparing for that conversation, our guide on talking to your doctor about menopause covers how to bring symptoms, history, and questions in a structured way.
Frequently asked questions
How long do hot flashes last on average?
The median is 7.4 years, based on the SWAN longitudinal cohort. About 4.5 of those years typically occur after the final menstrual period, not before it. Individual duration varies widely.
Do hot flashes go away after menopause?
For most women, yes — eventually. The median estimate has roughly 4.5 years of symptoms continuing after the final period. About one in ten women continue to experience hot flashes into their 70s.
Why are my hot flashes lasting so long?
Several factors are associated with longer duration: earlier onset of symptoms (before periods became irregular), race and ethnicity (Black women have the longest median duration in SWAN data), higher BMI, current smoking, anxiety or depression, and an “early-onset” trajectory pattern. None of these are choices — they reflect the actual biology of the variation.
Will treating hot flashes change how long they last?
Treatment manages symptoms for as long as you use it. It doesn’t appear to change the underlying biological timeline; women who stop hormone therapy often find that residual symptoms return, sometimes at similar intensity and sometimes milder. The right framing is that treatment makes the years you’re managing more livable, not that it shortens the years.
Should I just wait it out?
That’s a reasonable question if symptoms are mild. If symptoms are interfering with sleep, work, mood, or daily function, the realistic duration is years, and waiting it out means years of impaired quality of life. Effective treatments exist; the decision to use them is individual and reversible.
Can hot flashes start years after menopause?
Yes, though it’s less common. About a quarter of women have a late-onset trajectory where symptoms first appear around or after the final period. New-onset hot flashes years after menopause sometimes warrant evaluation for other causes (medication effects, thyroid dysfunction, less commonly other conditions), but they can also be normal late-onset menopausal physiology.
Sources
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015;175(4):531-539. SWAN cohort, n=1,449. (Median 7.4-year VMS duration; 4.5 years post-FMP; racial/ethnic differences.)
Tepper PG, Brooks MM, Randolph JF, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016;23(10):1067-1074. SWAN trajectory analyses.
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10. Menopause. 2012;19(4):387-395.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Prescription medications referenced in this article — including hormone therapy, fezolinetant, SSRIs, SNRIs, and gabapentin — require evaluation by a clinician, have specific contraindications and monitoring requirements, and are not appropriate for everyone.
